Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemoradiotherapy Plus Durvalumab in Resectable Stage III NSCLC
NCT03694236Phase 2Recruiting
- Sponsor
- Yonsei University
- Start
- Feb 2019
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Yonsei University. Primary endpoint: Treatment-Related Adverse Events at 5 years. Started Feb 2019; status: recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03694236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03694236.